| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0168-8278(05)80467-2 |
| P698 | PubMed publication ID | 8201224 |
| P2093 | author name string | G Rudolph | |
| A Stiehl | |||
| S Walker | |||
| W J Hofmann | |||
| L Theilmann | |||
| L Stiehl | |||
| P2860 | cites work | A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group | Q28243457 |
| Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial | Q35707325 | ||
| Ursodeoxycholic acid-induced changes of plasma and urinary bile acids in patients with primary biliary cirrhosis | Q39514969 | ||
| Improved survival with primary sclerosing cholangitis. A review of clinicopathologic features and comparison of symptomatic and asymptomatic patients | Q39770620 | ||
| Effect of ursodeoxycholic acid on bile acid metabolism in primary biliary cirrhosis. | Q42199158 | ||
| Abnormal urinary bile acids in a patient suffering from cerebrotendinous xanthomatosis during oral administration of ursodeoxycholic acid | Q42223427 | ||
| Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis | Q45103515 | ||
| Ursodeoxycholate reduces hepatotoxicity of bile salts in primary human hepatocytes. | Q50878460 | ||
| Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis: a 30-month pilot study. | Q54072767 | ||
| Natural history and prognostic variables in primary sclerosing cholangitis | Q67915561 | ||
| Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial | Q68019501 | ||
| Ursodeoxycholic acid for primary sclerosing cholangitis | Q68095108 | ||
| Acute effects of ursodeoxycholic and chenodeoxycholic acid on the small intestinal absorption of bile acids | Q68693124 | ||
| Asymptomatic primary sclerosing cholangitis treated with ursodeoxycholic acid | Q68842156 | ||
| Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial | Q69357047 | ||
| Comparison of the clinicopathologic features of primary sclerosing cholangitis and primary biliary cirrhosis | Q69880544 | ||
| Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? | Q69896715 | ||
| Primary sclerosing cholangitis and low-dose oral pulse methotrexate therapy. Clinical and histologic response | Q70021003 | ||
| Current concepts. Primary sclerosing cholangitis | Q70327279 | ||
| Primary sclerosing cholangitis: findings on cholangiography and pancreatography | Q70446406 | ||
| Analysis of bile acid glucuronides in urine: group separation on a lipophilic anion exchanger | Q70449036 | ||
| Enzymic analysis of steroid hormones | Q79283763 | ||
| P433 | issue | 1 | |
| P921 | main subject | placebo | Q269829 |
| primary sclerosing cholangitis | Q1058608 | ||
| bile duct disease | Q18556206 | ||
| P304 | page(s) | 57-64 | |
| P577 | publication date | 1994-01-01 | |
| P1433 | published in | Journal of Hepatology | Q15724402 |
| P1476 | title | Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period | |
| P478 | volume | 20 |
| Q71818799 | A 28-year-old woman with a combined hepatitic/cholestatic syndrome |
| Q35778052 | A network meta-analysis of the efficacy and side effects of UDCA-based therapies for primary sclerosing cholangitis. |
| Q26771816 | A review of the medical treatment of primary sclerosing cholangitis in the 21st century |
| Q43176309 | Bezafibrate for the treatment of primary sclerosing cholangitis |
| Q33591450 | Bile acid abnormalities in cholestatic liver diseases |
| Q24234678 | Bile acids for primary sclerosing cholangitis |
| Q24248730 | Bile acids for primary sclerosing cholangitis |
| Q34027631 | Biliary tract inflammatory disorders: primary sclerosing cholangitis and primary biliary cirrhosis |
| Q92465727 | British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis |
| Q37182946 | Clinical features and management of primary sclerosing cholangitis |
| Q64044703 | Clinical guidelines for primary sclerosing cholangitis 2017 |
| Q35068031 | Current management of primary biliary cirrhosis and primary sclerosing cholangitis |
| Q34408950 | Current status of therapy in autoimmune liver disease |
| Q43878341 | Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment |
| Q34687676 | Drug therapy of primary biliary diseases: classical and modern strategies. |
| Q45045457 | Effect of high-dose ursodeoxycholic acid on its biliary enrichment in primary sclerosing cholangitis |
| Q74429593 | Effect of tauroursodeoxycholic acid on bile-acid-induced apoptosis and cytolysis in rat hepatocytes |
| Q44229544 | Effect of ursodeoxycholic acid on hepatic steatosis in rats |
| Q41564193 | Effects of bile acids on hepatocellular signaling and secretion |
| Q73167014 | Efficacy of ursodeoxycholic acid treatment and endoscopic dilation of major duct stenoses in primary sclerosing cholangitis. An 8-year prospective study |
| Q36119492 | Endoscopic treatment of dominant stenoses in patients with primary sclerosing cholangitis |
| Q37156930 | Endoscopy in the management of primary sclerosing cholangitis |
| Q71603498 | Evidence for an overlap syndrome of autoimmune hepatitis and primary sclerosing cholangitis |
| Q33662086 | Hepatobiliary manifestations of inflammatory bowel disease |
| Q36750284 | High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis |
| Q43284332 | High-dose ursodeoxycholic acid in the treatment of primary sclerosing cholangitis: throwing the urso out with the bathwater? |
| Q46907665 | Impact of inflammatory bowel disease and ursodeoxycholic acid therapy on small-duct primary sclerosing cholangitis |
| Q51165355 | In PSC with colitis treated with UDCA, most colonic carcinomas develop in the first years after the start of treatment. |
| Q34410105 | Increased gall bladder volume in primary sclerosing cholangitis |
| Q77373443 | Influence of cholestasis on absorption of ursodeoxycholic acid |
| Q73832293 | Lack of complications following short-term stent therapy for extrahepatic bile duct strictures in primary sclerosing cholangitis |
| Q55111560 | Management Of Primary Sclerosing Cholangitis. |
| Q33591454 | Mechanism of hepatoprotective action of bile salts in liver disease |
| Q35734498 | Mechanisms of action and therapeutic efficacy of ursodeoxycholic acid in cholestatic liver disease |
| Q72996759 | Medical treatment for primary sclerosing cholangitis: risk versus benefit |
| Q81724957 | Medical treatment of primary biliary cirrhosis and primary sclerosing cholangitis |
| Q44503500 | Medical treatment of primary sclerosing cholangitis with ursodeoxycholic acid |
| Q37254347 | Medical treatment of primary sclerosing cholangitis: a role for novel bile acids and other (post-)transcriptional modulators? |
| Q45163892 | Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial |
| Q37182958 | Overlap syndromes among autoimmune liver diseases |
| Q26830851 | Overlap syndromes: an emerging diagnostic and therapeutic challenge |
| Q38833243 | Pharmacological interventions for primary sclerosing cholangitis: an attempted network meta-analysis. |
| Q77129334 | Primary Sclerosing Cholangitis |
| Q34210604 | Primary biliary cirrhosis and primary sclerosing cholangitis |
| Q34756048 | Primary prevention of colorectal cancer: diet and drugs |
| Q44736208 | Primary sclerosing cholangitis |
| Q79866264 | Primary sclerosing cholangitis |
| Q73127658 | Primary sclerosing cholangitis in Japan--analysis of 192 cases |
| Q37058852 | Primary sclerosing cholangitis, autoimmune hepatitis and overlap syndromes in inflammatory bowel disease |
| Q34498568 | Primary sclerosing cholangitis: diagnosis and management |
| Q26829216 | Primary sclerosing cholangitis: diagnosis and treatment |
| Q47112995 | Primary sclerosing cholangitis: diagnostic and management challenges |
| Q34382536 | Primary sclerosing cholangitis: updates in diagnosis and therapy |
| Q43046283 | Recurrence and rejection in liver transplantation for primary sclerosing cholangitis |
| Q73011043 | Single or multiple dose ursodeoxycholic acid for cholestatic liver disease: biliary enrichment and biochemical response |
| Q35046523 | The management of primary sclerosing cholangitis |
| Q81048479 | The management of primary sclerosing cholangitis |
| Q81194314 | The medical management of primary sclerosing cholangitis |
| Q34182672 | Treatment Options for Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis |
| Q81526242 | Treatment of Biliary Problems in Inflammatory Bowel Disease |
| Q34342199 | Treatment of autoimmune liver disease: current and future therapeutic options |
| Q34027595 | Treatment of primary biliary cirrhosis and primary sclerosing cholangitis: use of ursodeoxycholic acid |
| Q80055608 | Treatment of primary sclerosing cholangitis |
| Q44503507 | Treatment of primary sclerosing cholangitis with low-dose ursodeoxycholic acid: results of a retrospective Italian multicentre survey |
| Q34330984 | Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders'. |
| Q77598543 | Ursodeoxycholic acid in cholestasis: potential mechanisms of action and therapeutic applications |
| Q36727616 | Ursodeoxycholic acid in the treatment of liver diseases |
| Q77386849 | Ursodeoxycholic acid therapy for primary sclerosing cholangitis: results of a 2-year randomized controlled trial to evaluate single versus multiple daily doses |
| Q40457634 | Ursodeoxycholic acid therapy of chronic cholestatic conditions in adults and children |
| Q33866782 | Ursodeoxycholic acid treatment of vanishing bile duct syndromes |
| Q79320444 | [Treatment of cholestatic hepatic diseases: more than the substitution of fat soluble vitamins?] |
Search more.